Phio Pharmaceuticals Corp (PHIO)

$PHIO Are you all keeping an eye on BIAF?

Phio Pharmaceuticals Corp. (NASDAQ: $PHIO), a B2i Digital Featured Company, will present at a fireside chat hosted by FORCE Family Office tomorrow, March 18, 2026, at 4:00 PM ET / 1:00 PM PT. President and CEO Robert Bitterman will discuss the company’s approach to treating skin cancer, recent clinical progress from the completed Phase 1b trial, and the path toward the next stage of development. Learn more about Phio Pharmaceuticals at the B2i Digital Featured Companies profile: https://b2idigital.com/phio-pharmaceuticals-corp-1 Phio’s lead program, PH-762, uses the company’s proprietary INTASYL® siRNA gene silencing technology to target the PD-1 gene by injecting directly into the tumor rather than systemically infusing the entire body. The Phase 1b trial treatment phase was completed in January 2026, with an 85% pathological response rate in the final dose cohort. There were no immune-related or treatment-limiting toxicities observed in a 20-fold dose escalation across the five cohorts. There are currently no FDA-approved drug products for early-stage cutaneous squamous cell carcinoma. cSCC is the second largest incidence of solid tumors in the U.S., making surgery a standard treatment option. FORCE Family Office is a network of more than 200,000 family office representatives worldwide, hosting events connecting family offices with public and private companies for co-investment, education, and research. Register here: https://forcefamilyoffice.com/events/healthcare/phio-pharma-upcoming-march-18-2026/ Phio Pharmaceuticals Corp. is led by Robert Bitterman, President and Chief Executive Officer. To learn more about the company, visit www.phiopharma.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $PHIO $BIOTECH $CANCER.X $ONCOLOGY $RNAI $CLINICALTRIALS $NASDAQ

$PHIO https://finance.yahoo.com/news/phio-pharmaceuticals-announces-groundbreaking-approach-153000690.html

$PHIO pump!

$BRTX let’s goo 🔥$CTMX $PHIO $HCWB all doing well $TOVX just starting and don’t forget keep $BRTX get in early ‼️🔥🔥 NFA

https://nfne.ws/288680 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

$PHIO It seems like a good basis to get back into the game

Treasure Thursday Watchlist Pt.8 $VEEE $PHIO $FMFC $ONDS $RCAT Let's Pop Off Tomorrow

$PHIO Gradually move up, then drop some news and take off 🚀

$KALA This is overdue for a squeeze! IMO lots of hype a long time back that never came to be. Now??? $PHIO

$PHIO This company was previously called RXII. Changed the name back in 2018. Same story. Dilution, dilution, dilution until near worthless. Wonder what the next name will be.

The B2i Digital team is pleased to announce that Phio Pharmaceuticals Corp. (Nasdaq: $PHIO), a B2i Digital Featured Company, is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Thursday, March 12, 2026, at 11:00 AM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum For the full B2i Digital profile of Phio Pharmaceuticals, please visit: https://b2idigital.com/phio-pharmaceuticals-corp-1 Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Phio Pharmaceuticals is developing therapeutics using INTASYL, a chemically modified siRNA technology designed to silence specific genes that hinder the immune system’s ability to fight cancer, with a focus on immuno-oncology. Unlike many siRNA approaches that rely on complex delivery systems such as lipid nanoparticles, INTASYL compounds are engineered to self-deliver into cells without additional formulations, simplifying administration and potentially reducing toxicity. Presenting on behalf of Phio Pharmaceuticals will be Robert Bitterman, President and Chief Executive Officer. Mr. Bitterman has served on the company’s board since 2012 and assumed his current role in February 2023. He previously founded and served as President and CEO of Cutanea Life Sciences, a company focused on innovative treatments for diseases of the skin, until its acquisition by Biofrontera in 2019. Earlier in his career he held executive roles at Isolagen and Dermik Laboratories and various positions at Aventis. He holds an A.B. in Economics from the College of the Holy Cross and an MBA from Boston University. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5269944/phio-pharmaceuticals-corp-nasdaq-phio?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Phio Pharmaceuticals, visit: https://phiopharma.com/investors/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.